Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Completed initial public offering (“IPO”) raising net proceeds of $31.6 millionAppointed Anne Morrissey to the Board of Directors, an industry expert with decades of medical device experienceInitiated...
-
First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers ATLANTA, July 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:...
-
ATLANTA, June 24, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today announced the appointment of Anne Morrissey to the...
-
ATLANTA, June 17, 2021 (GLOBE NEWSWIRE) -- Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions and next-generation advancements providing...
-
ATLANTA, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Femasys, Inc., a medical technology company developing a platform of innovative in-office solutions for women’s healthcare today announced that the first...
-
ATLANTA, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical solutions that improve women’s healthcare, today announced that Kathy Lee-Sepsick, Chief Executive Officer...
-
- Funding to support pivotal testing of non-surgical permanent contraception solution FemBloc™ - - IDE approval granted by FDA for U.S. clinical trial of FemBloc; study to start early 2017 - ...
-
ATLANTA, March 23, 2016 (GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical devices for the women's healthcare market today announced that Fred Aslan, Founder and Chief Executive...